Compound ID | 2293
Cilagicin BP
Class: Lipopeptide
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor. Binds to both C55-P and C55-PP |
| Target Pathogen: | Active against Staphylococcus aureus and Enterococcus faecium, vancomycin-reistant Enterococcus, Clostridioides difficile and Streptococcus pyogenes |
| Description: | Natural product from Paenibacillus mucilaginosus strains; predicted structure was chemically synthesized based on biosynthetic gene cluster(syn-BNP); an analogue of cilagin that shows no haemolytic activity or cytotoxicity (at 100 ug/ml highest concentration tested vs MIC 0.125-2 ug/ml) and is able to reduce bacterial burden against Staphylococcus aureus and Streptococcus pyogenes |
| Year first mentioned: | 2022 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://www.science.org/doi/10.1126/science.abn4213 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.